ADCT-301

ADCT-301

About ADCT-301 (camidanlumab tesirine)

ADCT-301 (camidanlumab tesirine) is an antibody drug conjugate (ADC) composed of a monoclonal antibody that binds to CD25 (HuMax®-TAC, licensed from Genmab A/S), conjugated to a pyrrolobenzodiazepine (PBD) dimer toxin. Once bound to a CD25-expresing cell, ADCT-301 is internalized into the cell where enzymes release the PBD-based warhead. In addition to CD25-expressing tumor cells, ADCT-301 depletes CD25-positive Tregs in the local tumor environment, which enhances immune- mediated anti-tumor activity.

ADCT-301 is being evaluated in a pivotal Phase 2 clinical trial in patients with relapsed or refractory (R/R) Hodgkin lymphoma (ClinicalTrials.gov Identifier NCT04052997), as well as a Phase 1a/1b clinical trial in patients with R/R Hodgkin lymphoma and non-Hodgkin lymphoma (NCT02432235) and a Phase 1b clinical trial in solid tumors (NCT03621982).

Interim First-in-Human Data

ADCT-301 demonstrated significant clinical activity across a broad patient population and maintained a tolerability profile that we believe was manageable. Updated data from the ongoing 133-patient Phase 1 clinical trial of ADCT-301 were presented at the 60th American Society of Hematology (ASH) Annual Meeting. Check out our development on ADCT-402.

ADCT-301 / ASH 2018